KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD):
Gespeichert in:
| Körperschaft: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Nature Publ. Group
2009
|
| Schriftenreihe: | Kidney international
Supplement ; 113 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XII, 130 S. graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV035681875 | ||
| 003 | DE-604 | ||
| 005 | 20090909 | ||
| 007 | t | ||
| 008 | 090818s2009 d||| |||| 00||| eng d | ||
| 035 | |a (OCoLC)502146342 | ||
| 035 | |a (DE-599)BVBBV035681875 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-19 | ||
| 110 | 2 | |a Kidney Disease: Improving Global Outcomes |e Verfasser |0 (DE-588)10203760-7 |4 aut | |
| 245 | 1 | 0 | |a KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD) |
| 246 | 1 | 3 | |a Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD) |
| 264 | 1 | |a New York, NY |b Nature Publ. Group |c 2009 | |
| 300 | |a XII, 130 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Kidney international : Supplement |v 113 | |
| 650 | 4 | |a Bone Diseases | |
| 650 | 4 | |a Bones |x Diseases | |
| 650 | 4 | |a Chronic renal failure | |
| 650 | 4 | |a Kidney Diseases | |
| 650 | 4 | |a Kidney Failure, Chronic | |
| 650 | 4 | |a Kidneys |x Diseases | |
| 650 | 0 | 7 | |a Nierenkrankheit |0 (DE-588)4075399-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4137814-3 |a Richtlinie |2 gnd-content | |
| 689 | 0 | 0 | |a Nierenkrankheit |0 (DE-588)4075399-2 |D s |
| 689 | 0 | |C b |5 DE-604 | |
| 830 | 0 | |a Kidney international |v Supplement ; 113 |w (DE-604)BV000002249 |9 113 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017736133&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-017736133 | ||
Datensatz im Suchindex
| _version_ | 1804139388906504192 |
|---|---|
| adam_text | Titel: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chroni
Autor: Kidney Disease: Improving Global Outcomes
Jahr: 2009
http://www.kidney-international.org Contents
© 2009 kdigo VQL 76 j supPLEMENT t ¦, 3 | AUGUST 2009
kidney
INTERNATIONAL^
!
¦i^^ Sf KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention,
^¦ /¦jSBstfev^ and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder
gljMMMiO (CKD-MBD)
Oi°BAT C ^V Tables and figures
Svii Disclaimer
Sviii Work Group membership
Six KDIGO Board Members
Sx Abbreviations and acronyms
Sxi Reference Keys
Sxii Abstract
SI Foreword
S3 Chapter 1: Introduction and definition of CKD-MBD and the development of
the guideline statements
S9 Chapter 2: Methodological approach
S22 Chapter 3.1: Diagnosis of CKD-MBD: biochemical abnormalities
S32 Chapter 3.2: Diagnosis of CKD-MBD: bone
S44 Chapter 3.3: Diagnosis of CKD-MBD: vascular calcification
S50 Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphorus
and maintaining serum calcium
S70 Chapter 4.2: Treatment of abnormal PTH levels in CKD-MBD
S90 Chapter 4.3: Treatment of bone with bisphosphonates, other osteoporosis
medications, and growth hormone
SI 00 Chapter 5: Evaluation and treatment of kidney transplant bone disease
S111 Chapter 6: Summary and research recommendations
S115 Biographic and disclosure information
S120 Acknowledgments
SI 21 References
http://www.kidney-international.org Contents
© 2009 KDIGO
TABLES
S4 Table 1. KDIGO classification of CKD-MBD and renal osteodystrophy
S10 Table 2. Grading of recommendations
SI2 Table 3. Screening criteria for systematic review topics
SI 3 Table 4. Questions for topics not related to treatments
SI 5 Table 5. Literature search yield of primary articles for systematic review topics
SI 8 Table 6. Grading of study quality for an outcome
SI 9 Table 7. GRADE system for grading quality of evidence for an outcome
SI 9 Table 8. Final grade for overall quality of evidence
SI 9 Table 9. Balance of benefits and harm
S20 Table 10. Implications of the strength of a recommendation
S20 Table 11. Determinants of the strength of a recommendation
526 Table 12. Suggested frequencies of serum calcium, phosphorus, and PTH measurements according to CKD stage
527 Table 13. Sources and magnitude of the variation in the measurement of serum calcium, phosphorus, PTH, and vitamin D
sterols
S30 Table 14. Vitamin D2 and D3 and their derivatives
S36 Table 15. Changes in bone histomorphometric measurements from patients in placebo groups of clinical trials or
longitudinal studies
540 Table 16. Relationship between fractures and PTH in patients with CKD-MBD
541 Table 17. Positive predictive value for iPTH and b-ALP to predict bone turnover in patients with CKD stage 5
S41 Table 18. Correlation between PTH or other serum markers and BMD
S52 Table 19. Phosphate-binding compounds
S63 Table 20. RCTs of phosphate binders in children with CKD
S63 Table 21. Summary table of RCTs examining the treatment of CKD-MBD with sevelamer-HCI vs calcium-containing
phosphate binders in CKD stages 3-5—description of population at baseline
563 Table 22. Summary table of RCTs examining the treatment of CKD-MBD with sevelamer-HCI vs calcium-containing
phosphate binders in CKD stages 3-5—intervention and results
564 Table 23. Evidence matrix for sevelamer-HCI vs calcium-containing phosphate binders in CKD stage 5D
565 Table 24. Evidence profile for the treatment of CKD-MBD with sevelamer-HCI vs calcium-containing phosphate binders in
CKD stage 5D
567 Table 25. Evidence matrix for lanthanum carbonate vs other phosphate binders in CKD stage 5D
568 Table 26. Evidence profile of lanthanum carbonate vs other phosphate binders in CKD stages 5D
569 Table 27. Summary table of RCT examining alternate HD regimens in CKD stage 5D—description of population at baseline
S69 Table 28. Summary table of RCT examining alternate HD regimens in CKD stage 5D—intervention and results
S69 Table 29. Adverse events of alternate HD regimens in CKD stage 5D
582 Table 30. RCTs of calcitriol or other vitamin D analogs in children with CKD
583 Table 31. Evidence matrix of calcitriol or vitamin D analogs vs placebo in CKD stages 3-5
584 Table 32. Evidence profile of treatment of CKD-MBD with calcitriol or vitamin D analogs vs placebo in CKD stages 3-5
585 Table 33. Evidence matrix for calcitriol vs vitamin D analogs in CKD stage 5D
586 Table 34. Evidence profile for calcitriol vs vitamin D analogs in CKD stage SD
587 Table 35, Evidence matrix for calcimimetics in CKD stage 5D
588 Table 36. Evidence profile for caicimimetics in CKD stage 5D
598 Table 37. Evidence matrix of blsphosphonates vs placebo/control in CKD stages 3-5
599 Table 38. Evidence profile of bisphosphonates vs placebo/control in CKD stages 3-5
5106 Table 39. RCTs of treatments for CKD-MBD in children with CKD stages 1-5T
5107 Table 40. Evidence matrix of calcitriol or vitamin D analogs vs placebo or calcium alone in CKD stages 1-5T
5108 Table 41. Evidence profile of caicitriol or vitamin D analogs vs placebo or calcium alone in CKD stages 1-5T
5109 Table 42. Evidence matrix of bisphosphonates vs control in CKD stages 1-5T
5110 Table 43. Evidence profile for the treatment of CKD-MBD with bisphosphonates vs control in CKD stages 1-5T
5111 Table 44. Summary of cumulative evidence matrix with patient-centered outcomes, other surrogate outcomes, and
biochemical outcomes
Kidnev International (2009J 76 (Suppt 1135, Sv-Svi Sv
contents ^ , .
5112 Table 45. Cumulative evidence matrix for ail treatment studies by outcome
5113 Table 46. Grading of recommendations
FIGURES
S5 Figure 1. Interpreting a surrogate outcome trial
S10 Figure 2. Evidence model
SI 7 Figure 3. Parameters of bone turnover, mineralization, and volume
524 Figure 4. Prevalence of abnormal mineral metabolism in CKD
525 Figure 5. Changes in serum calcium, phosphorus, and iPTH with time in hemodialysis patients of DOPPS countries
S28 Figure 6. PTH assays
S35 Figure 7. Prevalence of types of bone disease as determined by bone biopsy in patients with CKD-MBD
S35 Figure 8. Prevalence of histologic types of renal osteodystrophy in children with CKD stages 5-5D
535 Figure 9. Types of renal osteodystrophy before and after 1995
536 Figure 10. Prevalence of bone histology types by symptoms in patients with CKD stage 5D receiving HD treatment
537 Figure 11. Distribution of osteoporosis, osteopenia, and normal bone density by creatinine clearance in general
US population
S3S Figure 12. Overlap between osteoporosis and CKD stages 3-4
538 Figure 13. Bone mineral density in patients with CKD Stage 5D
S40 Figure 14. Correlation coefficients between bone formation rate as seen on bone biopsies and serum markers of PTH,
bone-specific ALP (BAP), osteocalcin (OC), and collagen cross-linking molecules (x-link)
in patients with CKD stages 5-5D
576 Figure 15. Comparison of PTH levels to underlying bone histology in chronic hemodialysis patients
577 Figure 16. Risk of all-cause mortality associated with combinations of baseline serum phosphorus and calcium categories by
PTH level
Additional information in the form of supplementary tables can be found online at http://www.nature.com/ki
Svr
|
| any_adam_object | 1 |
| author_corporate | Kidney Disease: Improving Global Outcomes |
| author_corporate_role | aut |
| author_facet | Kidney Disease: Improving Global Outcomes |
| author_sort | Kidney Disease: Improving Global Outcomes |
| building | Verbundindex |
| bvnumber | BV035681875 |
| ctrlnum | (OCoLC)502146342 (DE-599)BVBBV035681875 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01782nam a2200409 cb4500</leader><controlfield tag="001">BV035681875</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20090909 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">090818s2009 d||| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)502146342</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV035681875</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="110" ind1="2" ind2=" "><subfield code="a">Kidney Disease: Improving Global Outcomes</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)10203760-7</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD)</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Nature Publ. Group</subfield><subfield code="c">2009</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XII, 130 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Kidney international : Supplement</subfield><subfield code="v">113</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bone Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bones</subfield><subfield code="x">Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chronic renal failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Kidney Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Kidney Failure, Chronic</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Kidneys</subfield><subfield code="x">Diseases</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Nierenkrankheit</subfield><subfield code="0">(DE-588)4075399-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4137814-3</subfield><subfield code="a">Richtlinie</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Nierenkrankheit</subfield><subfield code="0">(DE-588)4075399-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Kidney international</subfield><subfield code="v">Supplement ; 113</subfield><subfield code="w">(DE-604)BV000002249</subfield><subfield code="9">113</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017736133&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-017736133</subfield></datafield></record></collection> |
| genre | (DE-588)4137814-3 Richtlinie gnd-content |
| genre_facet | Richtlinie |
| id | DE-604.BV035681875 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T21:43:18Z |
| institution | BVB |
| institution_GND | (DE-588)10203760-7 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-017736133 |
| oclc_num | 502146342 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-19 DE-BY-UBM |
| owner_facet | DE-355 DE-BY-UBR DE-19 DE-BY-UBM |
| physical | XII, 130 S. graph. Darst. |
| publishDate | 2009 |
| publishDateSearch | 2009 |
| publishDateSort | 2009 |
| publisher | Nature Publ. Group |
| record_format | marc |
| series | Kidney international |
| series2 | Kidney international : Supplement |
| spelling | Kidney Disease: Improving Global Outcomes Verfasser (DE-588)10203760-7 aut KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD) Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD) New York, NY Nature Publ. Group 2009 XII, 130 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Kidney international : Supplement 113 Bone Diseases Bones Diseases Chronic renal failure Kidney Diseases Kidney Failure, Chronic Kidneys Diseases Nierenkrankheit (DE-588)4075399-2 gnd rswk-swf (DE-588)4137814-3 Richtlinie gnd-content Nierenkrankheit (DE-588)4075399-2 s b DE-604 Kidney international Supplement ; 113 (DE-604)BV000002249 113 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017736133&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD) Kidney international Bone Diseases Bones Diseases Chronic renal failure Kidney Diseases Kidney Failure, Chronic Kidneys Diseases Nierenkrankheit (DE-588)4075399-2 gnd |
| subject_GND | (DE-588)4075399-2 (DE-588)4137814-3 |
| title | KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD) |
| title_alt | Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD) |
| title_auth | KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD) |
| title_exact_search | KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD) |
| title_full | KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD) |
| title_fullStr | KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD) |
| title_full_unstemmed | KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD) |
| title_short | KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD) |
| title_sort | kdigo clinical practice guideline for the diagnosis evaluation prevention and treatment of chronic kidney disease mineral and bone disorder ckd mbd |
| topic | Bone Diseases Bones Diseases Chronic renal failure Kidney Diseases Kidney Failure, Chronic Kidneys Diseases Nierenkrankheit (DE-588)4075399-2 gnd |
| topic_facet | Bone Diseases Bones Diseases Chronic renal failure Kidney Diseases Kidney Failure, Chronic Kidneys Diseases Nierenkrankheit Richtlinie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017736133&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000002249 |
| work_keys_str_mv | AT kidneydiseaseimprovingglobaloutcomes kdigoclinicalpracticeguidelineforthediagnosisevaluationpreventionandtreatmentofchronickidneydiseasemineralandbonedisorderckdmbd AT kidneydiseaseimprovingglobaloutcomes clinicalpracticeguidelineforthediagnosisevaluationpreventionandtreatmentofchronickidneydiseasemineralandbonedisorderckdmbd |